China-France Collaboration Fund Completes Its First Investment in Dutch Ophthalmic Innovator DORC

Oriza Holdings (hereinafter referred to as “Oriza”) announced today that its managed Sino-French cooperation fund has completed an €80 million investment in Dutch Ophthalmic Research Center B.V. (hereinafter referred to as “Dutch Ophthalmic” or “DORC”), a global leader in vitreoretinal surgical equipment.

This investment marks the first for the China-France Cooperation Fund, which seeks to invest in French and European companies operating in high-growth sectors in China, while actively pursuing growth opportunities for its portfolio companies. In the China-France Cooperation FundJin ChengPrior to its establishment, this investment was already included as part of Eurazeo’s portfolio and reflected in the financial statements. This investment will not affect other funds under Eurazeo, particularly Eurazeo Capital IV, which had previously invested in Dutch Ophthalmic Research Center B.V. Currently, Eurazeo has contributed 50% of the capital raised for the Sino-French cooperation fund. As a result, this investment has had a positive impact of €40 million on Eurazeo’s cash position.

Dutch Ophthalmic Research Center B.V. (DORC) is a portfolio company of Eurazeo Capital, a large-cap buyout fund. DORC designs, manufactures, and distributes disposable and reusable ophthalmic surgical instruments, fluids, and equipment, with a particular focus on those used in vitreoretinal surgery. Renowned for its innovation, the company serves more than 5,700 surgeons across 80 countries and regions. With over 500 employees worldwide, DORC holds a strong market position in Europe and the United States. In 2019, the company reported annual revenue of €135 million.

The investment from the China-France Cooperation Fund is beneficial for Dutch Ophthalmic Research Center B.V. to fully leverage DORC, China Investment Corporation, andBNP Paribasrespective advantages, accelerating DORC’s further development in the Chinese market, which is growing at a rate of 15%–20%. The fund has already assisted Dutch Ophthalmic Research Center B.V. in establishing an advisory committee composed of renowned Chinese surgeons to support its market entry and the launch of products tailored to the specific needs of the Chinese market.

By strategically positioning itself in the Chinese market, Dutch Ophthalmic Research Center (DORC) will become a global leader in vitreoretinal surgery.

AboutFranceDORCZeFund Group

· Eurazeo is a global leading investment group with a 140-year history, managing €18.8 billion in assets, of which €12.5 billion comes from third parties, and holding investments in 430 companies worldwide. Leveraging its expertise in private equity, venture capital, real estate, debt, and funds of funds, Eurazeo serves companies of all sizes. With over 300 professionals, Eurazeo provides industry experience, helps companies access global markets, establishes stable footholds tailored to their target markets, and supports their transformation and growth. Backed by a solid base of institutional and family shareholders, a robust financial structure, and a flexible investment perspective, Eurazeo offers long-term development support to its portfolio companies.

· Oryx Fund Group has offices in Paris, New York, São Paulo, Seoul, Shanghai, London, Luxembourg, Frankfurt, Berlin, and Madrid.

· ORYZE Fund Group is listed on the Paris Stock Exchange.